{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:02:44Z","timestamp":1784520164281,"version":"3.55.0"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2026,1]]},"abstract":"ABSTRACT<\/jats:title>\n \n Purpose<\/jats:title>\n Real\u2010world evidence (RWE) addresses clinical trial limitations by capturing more representative patient populations and improves evaluation of anticancer treatments, although it becomes available only years after market authorization. As many RWE sources capture only parts of the healthcare continuum, dataset linkage is necessary to enhance data richness. Linkage quality must be assessed to prevent information bias due to incomplete data linkage.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We evaluated diagnosis concordance for lung cancer (LC), melanoma, and renal cell cancer (RCC) in England. Patients were matched based on national health service (NHS) number, sex and date of birth. Eligible patients were drawn from the National Cancer Registry and Analysis Service (NCRAS), and matched with three other datasets: Clinical Research Practice Database Aurum (CPRD Aurum), Hospital Episode Statistics Admitted Patient Care (HES\u2010APC), and systemic anticancer treatment (SACT). Concordance was evaluated for cancer diagnosis and date of diagnosis. Determinants of non\u2010concordance were investigated to assess representativeness.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In total, 89\u2009797 patients with LC, melanoma or RCC were identified, and concordance of cancer diagnosis records between NCRAS, CPRD Aurum and HES\u2010APC exceeded 70%. Because patients are only registered in SACT upon receiving systemic anticancer treatment, matched numbers in SACT were significantly lower (3.0%\u201321.1%), as anticipated, particularly among patients over 80\u2009years of age. However, differences in patient characteristics across datasets were limited. Concordance analyses showed that the majority of cases with LC diagnoses were registered within 3\u2009months of the initial diagnosis within all data sources, whereas melanoma and RCC showed longer delays.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Given the high concordance, NCRAS data can be enriched with HES\u2010APC and CPRD Aurum, and further complemented by SACT for systemic therapy. Provided that SACT undergoes further validation, linkage between NCRAS, CPRD Aurum, HES\u2010APC, and SACT may be a promising resource for RWE generation in oncology research.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/pds.70299","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T01:24:39Z","timestamp":1768440279000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concordance of Lung Cancer, Melanoma, and Renal Cell Cancer Diagnosis Information Recorded in Health Care Databases in England: Analysis of Linkage Between Primary Care, Hospital Care, and Cancer Registry Data"],"prefix":"10.1002","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4907-4021","authenticated-orcid":false,"given":"Paul D.","family":"Kruithof","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy & Toxicology CARIM, Research Institute for Cardiovascular Disease, Maastricht University Medical Centre+ Maastricht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C.","family":"Souverein","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology & Clinical Pharmacology Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna H. M.","family":"Driessen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Toxicology CARIM, Research Institute for Cardiovascular Disease, Maastricht University Medical Centre+ Maastricht the Netherlands"},{"name":"Division of Pharmacoepidemiology & Clinical Pharmacology Utrecht Institute for Pharmaceutical Sciences, Utrecht University Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Diseases GROW Research Institute for Oncology and Reproduction, Maastricht University Medical Center+ Maastricht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Croes","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Toxicology CARIM, Research Institute for Cardiovascular Disease, Maastricht University Medical Centre+ Maastricht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin M. J. M.","family":"van Geel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy & Toxicology CARIM, Research Institute for Cardiovascular Disease, Maastricht University Medical Centre+ Maastricht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010019\u20100099\u20109"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01300"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21714"},{"key":"e_1_2_11_5_1","unstructured":"R.Pajouheshnia R.Gini G.Hall et\u00a0al. \u201cEmbracing the Diversity of Real\u2010World Data Sources \u201dInternational Society for Pharmacoepidemiology 2025 https:\/\/www.pharmacoepi.org\/resources\/ispe\u2010insights\/embracing\u2010the\u2010diversity\u2010of\u2010real\u2010world\u2010data\u2010sources\/."},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000312871"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz076"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx015"},{"key":"e_1_2_11_10_1","unstructured":"National Health Service (NHS) United Kingdom \u201cWelcome to Chemotherapy Daycare \u201d2025 https:\/\/www.uclh.nhs.uk\/patients\u2010and\u2010visitors\/patient\u2010information\u2010pages\/welcome\u2010chemotherapy\u2010daycare."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz137"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2023.102337"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon\u20102019\u20100669"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102703"},{"key":"e_1_2_11_15_1","unstructured":"Clinical Practice Research Datalink \u201cCPRD Aurum May 2022 (Version 2022.05.001) [Data Set] \u201dClinical Practice Research Datalink https:\/\/www.cprd.com\/cprd\u2010aurum\u2010may\u20102022\u2010dataset."},{"key":"e_1_2_11_16_1","volume-title":"National Clinical Coding Standards: OPCS\u20104","author":"Digital N.","year":"2017"},{"key":"e_1_2_11_17_1","unstructured":"Health Centre SCI \u201cNational Clinical Coding Standards\u2010ICD\u201010 \u201d 2013."},{"key":"e_1_2_11_18_1","unstructured":"Clinical Practice Research Datalink (CPRD) \u201cCPRD Aurum Glossary of Terms\/Data Definitions v2.0 \u201d2024 https:\/\/www.cprd.com\/sites\/default\/files\/2023\u201002\/CPRD%20Aurum%20Glossary%20Terms%20v2.pdf."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2021.04.006"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194904"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102020\u2010043442"},{"key":"e_1_2_11_22_1","unstructured":"National Cancer Registration and Analysis Service (NCRAS) Of NSO \u201cCancer Survival by Stage at Diagnosis for England (Experimental Statistics): Adults Diagnosed 2012 2013 and 2014 and Followed Up to 2015 \u201d2024 https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/bulletins\/cancersurvivalbystageatdiagnosisforenglandexperimentalstatistics\/adultsdiagnosed20122013and2014andfollowedupto2015."},{"key":"e_1_2_11_23_1","unstructured":"UK CR \u201cTargeted Cancer Drugs and Immunotherapy for Melanoma Skin Cancer \u201d2025 https:\/\/www.cancerresearchuk.org\/about\u2010cancer\/melanoma\/treatment\/targeted\u2010cancer\u2010drugs\u2010and\u2010immunotherapy."},{"key":"e_1_2_11_24_1","unstructured":"National Institute for Health and Care Excellence (NICE) \u201cIpilimumab for Previously Treated Advanced (Unresectable or Metastatic) Melanoma \u201d2024 https:\/\/www.nice.org.uk\/guidance\/ta268."},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100320"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2021.101971"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102020\u2010037719"},{"key":"e_1_2_11_28_1","unstructured":"National Health Service (NHS) England \u201cNational Diabetes Audit 2021\u201322 Report 1: Care Processes and Treatment Targets Detailed Analysis Report \u201d2025 https:\/\/digital.nhs.uk\/data\u2010and\u2010information\/publications\/statistical\/national\u2010diabetes\u2010audit\/report\u20101\u2010care\u2010processes\u2010and\u2010treatment\u2010targets\u20102021\u201022\u2010full\u2010report\/section\u20101\u2010\u2010\u2010incidence\u2010and\u2010prevalence\u201017\u201018\u2010\u2010\u201021\u201022\u2010copy."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.70299","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.70299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T03:24:34Z","timestamp":1784517874000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.70299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/pds.70299"],"URL":"https:\/\/doi.org\/10.1002\/pds.70299","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70299"}}